These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Role of newer fluoroquinolones in lower respiratory tract infections. Lode H; Allewelt M J Antimicrob Chemother; 2002 May; 49(5):709-12. PubMed ID: 12003962 [No Abstract] [Full Text] [Related]
7. Gemifloxacin: survival of the fittest. Mandell L J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597 [TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Blondeau JM; Hansen GT Expert Opin Pharmacother; 2001 Feb; 2(2):317-35. PubMed ID: 11336589 [TBL] [Abstract][Full Text] [Related]
9. New concepts in antimicrobial therapy for emergency department infections. Talan DA Ann Emerg Med; 1999 Oct; 34(4 Pt 1):503-16. PubMed ID: 10532910 [No Abstract] [Full Text] [Related]
10. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. Bishai W Clin Ther; 2002 Jun; 24(6):838-50; discussion 837. PubMed ID: 12117077 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351 [TBL] [Abstract][Full Text] [Related]
12. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections? Momméja-Marin H; Carbon C Drugs; 1999 Jun; 57(6):851-3. PubMed ID: 10400400 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the clinical efficacy and safety of injectable quinolones in the treatment of respiratory tract infections (discussion)]. Kohno S; Watanabe A; Mikasa K; Asano K Jpn J Antibiot; 2003 Apr; 56(2):93-104. PubMed ID: 12825412 [No Abstract] [Full Text] [Related]
15. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Balfour JA; Lamb HM Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103 [TBL] [Abstract][Full Text] [Related]
16. Role of newer fluoroquinolones in lower respiratory tract infections. Lode H; Allewelt M J Antimicrob Chemother; 2002 Jul; 50(1):151-4. PubMed ID: 12613473 [No Abstract] [Full Text] [Related]
17. Fluoroquinolones for respiratory infections: too valuable to overuse. Williams JH Chest; 2001 Dec; 120(6):1771-5. PubMed ID: 11742900 [No Abstract] [Full Text] [Related]
18. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment? Norrby SR J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879 [No Abstract] [Full Text] [Related]
19. Drug not considered a first-line agent. Lexchin J Can Fam Physician; 1998 Nov; 44():2376. PubMed ID: 9839049 [No Abstract] [Full Text] [Related]
20. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin. Medeiros EA Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]